- Isomorphic Labs raises $600 million in its first external funding round to accelerate AI-driven drug discovery efforts.
- Backed by Thrive Capital, GV, and Alphabet, the funding supports clinical trial ambitions and top-tier talent recruitment.
- Built on DeepMind’s AlphaFold technology, the company has secured deals with Eli Lilly and Novartis worth up to $3 billion.
Isomorphic Labs, an artificial intelligence-driven drug discovery company spun out from DeepMind in 2021, has raised $600 million in its first round of external funding. The funding was led by Thrive Capital, with participation from GV and Alphabet, the parent company of Google. This significant investment marks a major milestone for the company as it scales its efforts in revolutionizing pharmaceutical research through AI.
The new capital will be used to accelerate development of Isomorphic Labs’ AI-powered drug design platform. With ambitions to bring its AI-discovered drug candidates to clinical trials, the company is focusing on expanding both its research capabilities and operational infrastructure. The investment will also enable Isomorphic to recruit top-tier scientific talent, a critical step toward maintaining its competitive edge in the rapidly evolving biotech sector.
Founded by DeepMind co-founder Demis Hassabis, Isomorphic Labs leverages advanced AI technologies developed by DeepMind, including AlphaFold—a groundbreaking model capable of predicting the 3D structure of proteins. This core technology underpins the company’s approach to simulating and optimizing potential drug compounds with unprecedented speed and accuracy.
In 2023, Isomorphic Labs entered into strategic partnerships with pharmaceutical giants Eli Lilly and Novartis. These collaborations could yield up to $3 billion in milestone payments, providing industry validation of the startup’s AI platform and its potential to transform drug development pipelines.
The company’s scientific achievements have not gone unnoticed. In 2024, Hassabis and DeepMind researcher John Jumper were recognized with a Nobel Prize in Chemistry for their work on AlphaFold, further cementing the significance of AI in reshaping modern biology and medicine. With fresh funding and growing momentum, Isomorphic Labs is poised to play a pivotal role in the future of drug discovery.
